|
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
|
Written by: J. Smith |
Hits: 348
|
|
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
|
Written by: J. Smith |
Hits: 286
|
|
Teva Launches First Generic GLP-1 for Obesity
|
Written by: J. Smith |
Hits: 201
|
|
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
|
Written by: J. Smith |
Hits: 228
|
|
FDA Expands Repatha Access to More High-Risk Adults
|
Written by: J. Smith |
Hits: 384
|
|
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
|
Written by: J. Smith |
Hits: 418
|
|
Signos Press Release Raises Questions About FDA Clearance Claims
|
Written by: J. Smith |
Hits: 452
|
|
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
|
Written by: J. Smith |
Hits: 412
|
|
FDA Approves Wegovy for MASH Treatment
|
Written by: J. Smith |
Hits: 414
|
|
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
|
Written by: J. Smith |
Hits: 464
|
